REVIEW PAPER
Autoimmune hepatitis and primary sclerosing cholangitis overlap syndrome in inflammatory bowel diseases
1
Department of Gastroenterology, Hepatology, Feeding Disorders, and Paediatrics, The Children’s Memorial Health Institute, Warsaw, Poland
Submission date: 2023-03-07
Final revision date: 2023-05-10
Acceptance date: 2023-05-14
Publication date: 2023-09-29
Corresponding author
Joanna Saganek
Joanna Saganek, Department of Gastroenterology, Hepatology, Feeding Disorders, and Paediatrics, The Children’s Memorial Health Institute, Warsaw, Poland
Joanna Saganek, Department of Gastroenterology, Hepatology, Feeding Disorders, and Paediatrics, The Children’s Memorial Health Institute, Warsaw, Poland
Pediatr Pol 2023;98(3):236-241
KEYWORDS
TOPICS
ABSTRACT
A close relationship between inflammatory bowel diseases (IBD) and hepatobiliary disorders, such as autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC), is well established. Hepatobiliary manifestations occur in 30% of patients with IBD, and 5% develop chronic liver disease. The spectrum of symptoms of the overlap syndrome ranges from asymptomatic elevated liver function tests to serious diseases. The pathogenesis of liver complications in IBD is not fully recognized. It may either have an autoimmune background or be caused by intestinal inflammation, metabolic impairment, or drug toxicity. The aim of this review is to summarize AIH and PSC overlap syndrome in IBD.
REFERENCES (59)
1.
Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract 2012; 2012: 642923.
2.
Rojas-Feria M, Castro M, Suárez E, et al. Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver. World J Gastroenterol 2013; 19: 7327-7340.
3.
Laborda TJ, Jensen MK, Kavan M, et al. Treatment of primary sclerosing cholangitis in children. World J Hepatol 2019; 11: 19-36.
4.
Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol 2008; 14: 3350-3359.
5.
Adike A, Carey EJ, Lindor KD. Primary sclerosing cholangitis in children versus adults: lessons for the clinic. Expert Rev Gastroenterol Hepatol 2018; 12: 1025-1032.
6.
Feldstein AE, Perrault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003; 38: 210-217.
7.
Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first- degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6: 939-943.
8.
Gupta A, Bowlus CL. Primary sclerosing cholangitis: etiopathogenesis and clinical management. Front Biosci (Elite Ed) 2012; 4: 1683-1705.
9.
Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006; 26: 22-30.
10.
Little R, Wine E, Kamath BM, et al. Gut microbiome in primary sclerosing cholangitis: a review. World J Gastroenterol 2020; 26: 2768-2780.
11.
Li Y, Tang R, Leung PSC, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev 2017; 16: 885-896.
12.
Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis - a comprehensive review. J Hepatol 2017; 67: 1298-1323.
13.
Fagundes EDT, Ferreira AR, Hosken CC, et al. Primary sclerosing cholangitis in children and adolescents. Arq Gastroenterol 2017; 54: 286-291.
14.
Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-2055.
15.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
16.
Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015; 110: 646-659.
17.
Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814.
18.
Harnois DM, Angulo P, Jorgensen RA, et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 1558-1562.
19.
Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-1472.
20.
Cullen SN, Rust C, Fleming K, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008; 48: 792-800.
21.
Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695.
22.
Damman JL, Rodriguez EA, Ali AH, et al. Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. Aliment Pharmacol Ther 2018; 47: 886-895.
23.
Shah A, Crawford D, Burger D, et al. Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis. Semin Liver Dis 2019; 39: 432-441.
24.
Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis – a pilot study. Aliment Pharmacol Ther 2013; 37: 604-612.
25.
Hubers LM, Maillette de Buy Wenniger LJ, Doorenspleet ME, et al. IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol 2015; 48: 198-206.
26.
Beuers U, Maillette de Buy Wenniger LJ, Doorenspleet M, et al. IgG4-associated cholangitis. Dig Dis 2014; 32: 605-608.
27.
Núñez FP, Quera PR, Gomollón F. Primary sclerosing cholangitis and inflammatory bowel disease: Intestine-liver interrelation. Gastroenterol Hepatol 2019; 42: 316-325.
28.
Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008; 14: 331-337.
29.
Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet 2018; 391: 2547-2559.
30.
Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-39.
31.
Singh S, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol 2013; 11: 898-907.
32.
Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678.
33.
Krugliak Cleveland N, Rubin DT, Hart J, et al. Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon. Clin Gastroenterol Hepatol 2018; 16: 68-74.
34.
Ricciuto A, Kamath BM, Griffiths AM. The IBD and PSC phenotypes of PSC-IBD. Curr Gastroenterol Rep 2018; 20:16.
35.
Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patiets with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54.
36.
El-Matary W, Guthery SL, Amir AZ, et al. Colorectal dysplasia and cancer in pediatric-onset ulcerative colitis associated with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2021; 19: 1067-1070.e2.
37.
Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 24-30.
38.
Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523-526.
40.
Floreani A, Liberal R, Vergani D, et al. Autoimmune hepatitis: contrasts and comparisons in children and adults – a comprehensive review. J Autoimmun 2013; 46: 7-16.
41.
Mieli-Vergani G, Vergani D, Baumann U, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr 2018; 66: 345-360.
42.
Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. Nat Rev Dis Primers 2018; 4: 18017.
43.
Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-547.
44.
Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002; 22: 353-364.
45.
Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance And Guidelines from the American Association for the Study of Liver Diseases. Hepatology 2020; 72: 671-722.
46.
Liberal R, Krawitt EL, Vierling JM, et al. Cutting edge issues in autoimmune hepatitis. J Autoimmun 2016; 75: 6-19.
47.
Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol 2020; 27: 58-69.
48.
Lamers MM, van Oijen MG, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol 2010; 53: 191-198.
49.
Lohse AW, Chazouillères O, Dalekos G, et al. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015; 63: 971-1004.
50.
Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14: 325-331.
51.
Restellini S, Chazouillères O, Frossard JL. Hepatic manifestations of inflammatory bowel diseases. Liver Int 2017; 37: 475-489.
52.
Gaspar R, Macedo G, Branco CC. Liver manifestations and complications in inflammatory bowel disease: a review. World J Hepatol 2021; 13: 1956-1967.
53.
Abdalian R, Dhar P, Jhaveri K, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: Evaluating the role of routine magnetic resonance imaging. Hepatology 2008; 47: 949-957.
54.
Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol 2013; 27: 417-423.
55.
Rust C, Beuers UH. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008; 14: 3368-3373.
56.
Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology 2001; 33: 994-1002.
57.
Malik TA, Gutierrez AM, McGuire B, et al. Autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome complicated by Crohn’s disease. Digestion 2010; 82: 24-26.
58.
Ballotin VR, Bigarella LG, Riva F, et al. Primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome associated with inflammatory bowel disease: a case report and systematic review. World J Clin Cases 2020; 8: 4075-4093.
59.
Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013; 58: 326-343.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
